NOVATO, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Emil D.
NOVATO, Calif., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Emil D.
Dojolvi is the only approved therapy for this rare, life-threatening metabolic disorder NOVATO, Calif., Aug. 23, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic
NOVATO, Calif., Aug. 17, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of non-qualified stock options to purchase an
NOVATO, Calif., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Emil D.
Second quarter 2021 total revenue of $87.0 million including Crysvita 1 revenue to Ultragenyx of $44.7 million 2021 Crysvita revenue in Ultragenyx territories 1 guidance of $180 million to $190 million reaffirmed Strong Dojolvi launch continues with approximately 220 patients on reimbursed
NOVATO, Calif., July 27, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel therapies for serious rare and ultra-rare genetic diseases, today announced that it will host a conference call on Monday, August 2, 2021
Phase 1/2 study is expected to initiate enrollment in the second half of 2021 NOVATO, Calif., July 27, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and
NOVATO, Calif., June 30, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced the appointment of Corsee Sanders,
Patient enrollment to begin in early second half of 2021 in U.K. and Canada GeneTx to submit revised protocol to U.S. Food and Drug Administration seeking study resumption in U.S. following May meeting SARASOTA, Fla. and NOVATO, Calif., June 10, 2021 (GLOBE NEWSWIRE) -- GeneTx Biotherapeutics LLC
